These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 14585168)

  • 1. Genetic factors underlying prostate cancer.
    Luo JH; Yu YP
    Expert Rev Mol Med; 2003 Apr; 5(12):1-26. PubMed ID: 14585168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular pathology of prostate cancer.
    Hughes C; Murphy A; Martin C; Sheils O; O'Leary J
    J Clin Pathol; 2005 Jul; 58(7):673-84. PubMed ID: 15976331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrative analysis of genomic aberrations associated with prostate cancer progression.
    Kim JH; Dhanasekaran SM; Mehra R; Tomlins SA; Gu W; Yu J; Kumar-Sinha C; Cao X; Dash A; Wang L; Ghosh D; Shedden K; Montie JE; Rubin MA; Pienta KJ; Shah RB; Chinnaiyan AM
    Cancer Res; 2007 Sep; 67(17):8229-39. PubMed ID: 17804737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Searching for suppressor genes in prostate cancer.
    Peehl DM
    Cancer Surv; 1991; 11():25-34. PubMed ID: 1668728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression alterations in human prostate cancer.
    Luo JH
    Drugs Today (Barc); 2002 Oct; 38(10):713-9. PubMed ID: 12582456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single cell genomics reveals activation signatures of endogenous SCAR's networks in aneuploid human embryos and clinically intractable malignant tumors.
    Glinsky GV
    Cancer Lett; 2016 Oct; 381(1):176-93. PubMed ID: 27497790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of genomic alterations through coregulation analysis of closely linked genes: a frequent gain in 17q25.3 in prostate cancer.
    Bermudo R; Abia D; Benitez D; Carrió A; Vilella R; Ortiz AR; Thomson TM; Fernández PL
    Ann N Y Acad Sci; 2010 Oct; 1210():17-24. PubMed ID: 20973795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-regulation analysis of closely linked genes identifies a highly recurrent gain on chromosome 17q25.3 in prostate cancer.
    Bermudo R; Abia D; Ferrer B; Nayach I; Benguria A; Zaballos A; del Rey J; Miró R; Campo E; Martínez-A C; Ortiz AR; Fernández PL; Thomson TM
    BMC Cancer; 2008 Oct; 8():315. PubMed ID: 18973659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneously detection of genomic and expression alterations in prostate cancer using cDNA microarray.
    Jiang M; Li M; Fu X; Huang Y; Qian H; Sun R; Mao Y; Xie Y; Li Y
    Prostate; 2008 Oct; 68(14):1496-509. PubMed ID: 18366025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role and Mechanism of Epithelial-to-Mesenchymal Transition in Prostate Cancer Progression.
    Lo UG; Lee CF; Lee MS; Hsieh JT
    Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28973968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Network-based approach reveals Y chromosome influences prostate cancer susceptibility.
    Khosravi P; Gazestani VH; Asgari Y; Law B; Sadeghi M; Goliaei B
    Comput Biol Med; 2014 Nov; 54():24-31. PubMed ID: 25199846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global methylation analysis identifies PITX2 as an upstream regulator of the androgen receptor and IGF-I receptor genes in prostate cancer.
    Schayek H; Bentov I; Jacob-Hirsch J; Yeung C; Khanna C; Helman LJ; Plymate SR; Werner H
    Horm Metab Res; 2012 Jun; 44(7):511-9. PubMed ID: 22495974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular pathology of prostate cancer.
    Konishi N; Shimada K; Ishida E; Nakamura M
    Pathol Int; 2005 Sep; 55(9):531-9. PubMed ID: 16143027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA expression profiling in prostate cancer.
    Porkka KP; Pfeiffer MJ; Waltering KK; Vessella RL; Tammela TL; Visakorpi T
    Cancer Res; 2007 Jul; 67(13):6130-5. PubMed ID: 17616669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI3K/AKT pathway regulates E-cadherin and Desmoglein 2 in aggressive prostate cancer.
    Barber AG; Castillo-Martin M; Bonal DM; Jia AJ; Rybicki BA; Christiano AM; Cordon-Cardo C
    Cancer Med; 2015 Aug; 4(8):1258-71. PubMed ID: 26033689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Molecular analysis for prostate cancer].
    Ueda T; Suzuki H; Ichikawa T
    Nihon Rinsho; 2005 Feb; 63(2):213-7. PubMed ID: 15714968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 12-gene expression signature is associated with aggressive histological in prostate cancer: SEC14L1 and TCEB1 genes are potential markers of progression.
    Agell L; Hernández S; Nonell L; Lorenzo M; Puigdecanet E; de Muga S; Juanpere N; Bermudo R; Fernández PL; Lorente JA; Serrano S; Lloreta J
    Am J Pathol; 2012 Nov; 181(5):1585-94. PubMed ID: 23083832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor interaction analysis for chromosome 8 and DNA methylation alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancer.
    Schulz WA; Alexa A; Jung V; Hader C; Hoffmann MJ; Yamanaka M; Fritzsche S; Wlazlinski A; Müller M; Lengauer T; Engers R; Florl AR; Wullich B; Rahnenführer J
    Mol Cancer; 2007 Feb; 6():14. PubMed ID: 17280610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular biology of progression of prostate cancer.
    Nupponen N; Visakorpi T
    Eur Urol; 1999; 35(5-6):351-4. PubMed ID: 10325488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer.
    Hubbard GK; Mutton LN; Khalili M; McMullin RP; Hicks JL; Bianchi-Frias D; Horn LA; Kulac I; Moubarek MS; Nelson PS; Yegnasubramanian S; De Marzo AM; Bieberich CJ
    Cancer Res; 2016 Jan; 76(2):283-92. PubMed ID: 26554830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.